Viking Therapeutics Shares Drop After Oversubscribed Capital Raise
Viking Therapeutics (NASDAQ: VKTX) experienced a significant drop in its stock price, falling by approximately 14.5% after announcing an upsized capital raise of $275 million through common shares and $225 million via convertible senior notes due in 2023. The move followed positive preliminary results from the maintenance phase of its Phase 3 trial for VK2735, a key weight-loss drug candidate. The stock correction is attributed to investors reacting to the dilutive impact of the capital raise rather than any negative news about the clinical data itself. Management had previously announced plans to capitalize on recent share price gains following positive top-line results from an initial subcutaneous dosing study lasting 21 weeks, with a maintenance phase currently underway. The company aims to demonstrate dual formulation strategies for VK2735 by testing oral administration in the next stage of its trial. Despite today's drop, analysts remain optimistic about Viking Therapeutics' long-term prospects.
Tickers: $VKTX